Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has submitted a routine compliance certificate to BSE (Scrip Code: 524636) confirming that all securities dematerialised during the quarter ended 30 June 2025 have been properly processed. The company's Registrar and Transfer Agent, M/s Venture Capital and Corporate Investments Private Limited, certified that dematerialised share certificates were mutilated and cancelled, and ownership records were updated with NSDL and CDSL within the required 15-day window. The confirmation was shared with the stock exchanges where the company's shares are listed. The letter was signed by Managing Director Sai Sudhakar Vankineni on 21 July 2025.
This is a standard regulatory compliance filing with no material impact on the company's financials, operations, or share price. It only confirms routine procedural handling of share dematerialisation requests during the quarter.